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Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that is known to cause respiratory
tract infections in children and immunocompromised individuals. Given the difficulties of identifying hMPV by
conventional culture, molecular techniques could improve the detection of this virus in clinical specimens. In
this study, we developed a real-time reverse transcription-PCR (RT-PCR) assay designed to detect the four
genetic lineages of hMPV. This assay and a commercial real-time nucleic acid sequence-based amplification
(NASBA) assay (bioMe´rieux, Durham, NC) were used to determine the prevalence of hMPV in 114 immuno-
suppressed asymptomatic and symptomatic lung transplant recipients and 232 pediatric patients who were
being evaluated for pertussis. hMPV was detected in 4.3% of the immunosuppressed lung transplant recipients
and in 9.9% of children evaluated for pertussis. Both RT-PCR and NASBA assays were efficient in detection of
hMPV infection in respiratory specimens. Even though hMPV was detected in a small number of the lung
transplant recipients, it was still the most prevalent etiologic agent detected in patients with respiratory
symptoms. In both of these diverse patient populations, hMPV infection was the most frequent viral respiratory
tract infection identified. Given our findings, infection with hMPV infection should be determined as part of
the differential diagnosis of respiratory illnesses.
Human metapneumovirus (hMPV) is a negative-sense, sin-
gle-stranded RNA virus that was first described in 2001 as a
novel paramyxovirus isolated from the respiratory tract of chil-
dren in The Netherlands (23). Since its initial description,
hMPV has been reported worldwide (8, 9, 14, 15, 17, 22, 23, 26,
28), particularly in children and immunocompromised adults
(6, 18, 21). hMPV has two main genetic lineages, A and B, with
two subtypes for each lineage (A1, A2, B1, and B2) (19, 21, 24).
hMPV had gone unrecognized for many years because it dis-
plays very slow replication kinetics in vitro, does not replicate
efficiently in continuous cell lines, and requires trypsin for
growth in vitro (23). hMPV causes occasional upper respira-
tory tract infections, although lower respiratory tract infections
can result in bronchiolitis, pneumonitis, and asthma exacerba-
tion (7, 10, 23). Studies have closely associated a seasonal
incidence of hMPV infections during late winter (January to
April). In addition, 1.2 to 4.1% of asymptomatic individuals are
positive for hMPV RNA by reverse transcription-PCR (RT-
PCR), suggesting that inapparent infections are common (6,
23, 27).
Solid-organ transplant recipients, particularly lung trans-
plant recipients, are susceptible to opportunistic respiratory
infections that are mostly of unknown etiology. Among the
potential posttransplant complications, obliterative bronchiol-
itis is the most significant. Respiratory viral infections have
been postulated to be associated with the development of
obliterative bronchiolitis, since immunosuppression leaves
lung transplant recipients more susceptible to community-ac-
quired infections (11). In this study, we have developed and
compared a real-time RT-PCR assay targeting the nucleopro-
tein (N) gene and a nucleic acid sequence-based amplification
(NASBA) assay targeting the matrix gene for detection of
hMPV infection in respiratory specimens from lung transplant
recipients and children who were being evaluated for pertussis
to determine its prevalence in these two diverse patient pop-
ulations.
MATERIALS AND METHODS
Sample collection. Bronchoalveolar lavage (BAL) specimens were collected
from adult lung transplant recipients. Bronchoscopies with bronchoalveolar
lavage were performed at regular intervals according to University of Pittsburgh
Medical Center transplantation protocols (1, 3, 6, 9, and 12 months posttrans-
plant) and as indicated by symptomatic events such as fever, radiographic infil-
trates, and decreased forced expiratory flow as determined by spirometry. One
hundred microliters of BAL specimens was stored in lysis buffer (bioMe´rieux,
Durham, NC) at80°C in a total volume of 1 ml. Suspensions of nasopharyngeal
secretions were obtained from a collection maintained by the Pediatric Molec-
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ular Microbiology Laboratory at Children’s Hospital of Pittsburgh (PA). The
secretions were collected with Dacron swabs and suspended in 500 l of saline,
and the suspensions were stored at 80°C as single-use aliquots (i.e., 100 l)
until needed (25). The swab specimens had been obtained as part of routine
care of pediatric patients who were evaluated for pertussis between February
and May 2005.
Nucleic acid extraction. Isolation of viral nucleic acid from control material
and patient specimens was done using the NucliSens Automated Extractor
(bioMe´rieux, Durham, NC) according to the manufacturer’s instructions. Briefly,
100 l of sample was lysed in lysis buffer (bioMerieux, Durham, NC) for 30 min,
following which a fixed volume and concentration of equine arteritis virus (EAV)
was added as internal control for extraction and amplification in addition to
diluted silica per the manufacturer’s instructions. The solution was transferred
into a closed system cartridge and placed onto the instrument for extraction. The
procedure took approximately 1 h and the RNA was eluted in 50 l of elution
buffer (bioMerieux, Durham, NC), which was stored at 80°C in the same tube
until use.
Virus and viral RNA. Viral isolates of hMPV strains Can97-83 (strain A2) and
Can98-75 (strain B2) stored in TRIzol buffer were kindly provided by Dean
Erdman of the Centers for Disease Control and Prevention (Atlanta, GA).
Can97-83 viral RNA was kindly provided by Ursula Buchholz at the National
Institutes of Health (Bethesda, MD). Total RNA was extracted using the RNeasy
kit (QIAGEN, Alameda, CA). Equine arteritis virus (EAV) was obtained from
the American Type Culture Collection (VR-796; Rockville, MD) for preparation
of an internal control for the hMPV RT-PCR assays. The virus was inoculated
into a 75-cm2 flask of Vero cells near confluence. Infection resulted in detach-
ment of the monolayer from the flask in less than 24 h. The virus was harvested
from the supernatant following sonication and stored (500 l:500 l) in minimal
essential medium with 10% fetal bovine serum at 80°C. A 1/50 dilution of the
virus (106.25 50% tissue culture infectious doses/ml) was spiked into each spec-
imen prior to extraction.
Real-time RT-PCR. Reverse transcription and amplification of hMPV RNA
was performed in a single tube using the in-house-developed assay targeting the
nucleoprotein (N) gene. The primers Forward (5-CATCAGGTAATATCCCA
CAAAATCAG-3 and Reverse 5-GTGAATATTAAGGCACCTACACATAA
TAARA-3) and probe (5–6-carboxyfluorescein–TCAGCACCAGACACAC-
minor groove binding-3) were designed using Primer Express software (Applied
Biosystems). One-step RT qPCR MasterMix (Eurogentec, San Diego, CA) was
used according to the manufacturer’s instructions. This 25-l reaction consisted
of 2 reaction buffer, 8 mM MgCl2, 200 EuroScript RT (0.25 U/l), RNase
inhibitor (0.1 l), 300 nM forward primer, 300 nM reverse primer, Taq DNA
polymerase, 100 nM probe, template RNA, and sterile H2O. The amplification
was carried out using an ABI PRISM 7000 (Applied Biosystems, Foster City,
CA) with the following cycling conditions: RT step at 48°C for 30 min]; Taq
activation step at 95°C for 10 min for cycle, followed by 45 cycles of a PCR step
at 95°C for 15 s and 60°C for 1 min. Amplification of EAV served as an internal
control in every patient specimen to determine the integrity of the sample
controlling for both extraction and amplification procedures. The primers and
assay conditions for EAV amplification were as previously described (1). RT-
PCRs for hMPV and EAV were performed in separate wells.
Real-time NASBA. Real-time NASBA was performed using NucliSens Basic
kit reagents (bioMe´rieux) on an EasyQ Analyzer (bioMe´rieux, Durham, NC) for
120 min according to the manufacturer’s instructions. hMPV-specific primer/
beacon mix was provided by bioMe´rieux (Durham, NC) for virus amplification
and detection. Each sample was tested in a 20-l NASBA reaction mixture
containing 5 l of template, 5 l of enzyme (1 enzyme sphere diluted in 55 l of
enzyme diluent), and 10 l of reagent mastermix (1 reagent sphere, 80 l of reagent
diluent, 16 l of 80 mM KCl, 10 l of primer/beacon mix, and 14 l of H2O). RNA
was added to the reagent mastermix and incubated at 65°C for 2 min and 41°C
for 2 min. Following the incubation, the enzyme was added and mixed by briefly
flicking and spinning the tubes. The EasyQ analyzer was utilized for amplification
and detection.
Viral culture and immunofluorescent staining. Two R-Mix shell vials contain-
ing a mixed monolayer of mink lung cells (strain Mv1Lu) and human adenocar-
cinoma cells (strain A549) were inoculated with 200 l of clinical specimen
according to the manufacturer’s instructions (Diagnostic Hybrids, Athens, OH).
Each vial was centrifuged at 700  g for 60 min and incubated at 35°C. Screening
of the R-Mix shell vial at 18 to 24 h postinoculation was accomplished with the
first of the two vials. Coverslips were fixed with acetone and stained with a pool
of respiratory virus fluorescent antibodies (adenovirus, influenza A and B vi-
ruses, respiratory syncytial virus [RSV], and parainfluenza viruses 1 to 3) (Bar-
tels, Issaquah, WA) according to the manufacturer’s instructions. Positive spec-
imens were further identified with the second R-Mix shell vial by scraping and
spotting 8-well slides. These slides were fixed with acetone again and stained with
virus-specific monoclonal antibodies.
Construction of N-gene plasmid and RNA transcripts. The full-length hMPV
N gene was amplified by conventional two-step RT-PCR from the Can97-83 viral
RNA. A gene-specific primer downstream of the N-gene region was designed for
reverse transcription (5-GCCTTGCGAGACATTATGATTTG-3), and the
forward (5-GAAAATGTCTCTTCAAGGGATTCAC-3) and the reverse prim-
ers (5-GCCAATTTTGCCGCTTCAT-3) were used to amplify the full-length
N gene. The PCR product was gel purified using the Wizard SV Gel and PCR
Clean-Up System (Promega, Madison, WI) according to the manufacturer’s
instructions and ligated into the pGEM-T Easy Vector (Promega, Madison, WI).
Insertion of the correct sequences into the plasmid was confirmed by digesting
the plasmid with PstI (Promega, Madison, WI) at 37°C for 3 h. In vitro tran-
scription was performed under the control of the SP6 promoter using the Ribo-
max Large Scale RNA Production System (Promega, Madison, WI). The tran-
scripts were DNase treated and RNA purified by phenol-chloroform extraction
according to the manufacturer’s instructions. The concentration of hMPV N-
gene transcript was determined spectrophotometrically and used as a positive
control for real-time RT-PCR during each run.
FIG. 1. Sensitivity of hMPV real-time RT-PCR. (A and B) Amplification plot and the external standard curve generated by serially diluted
hMPV N-gene in vitro transcripts by real-time RT-PCR. The values shown in panel A represent hMPV RNA copies/RT-PCR. Based on copy
numbers of the in vitro-transcribed RNA standards, the lower detection limit is 100 RNA copies/RT-PCR by real-time RT-PCR.
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RESULTS
Sensitivity and specificity of molecular detection assays.
The sensitivity of the N-gene real-time RT-PCR assay using
serially diluted transcripts was 100 RNA copies/RT-PCR (Fig.
1). Using these serially diluted transcripts as external stan-
dards, hMPV strains A (Can97-83) and B (Can98-75) were
quantitated by real-time RT-PCR. Differences in sensitivities
of amplification between RT-PCR and NASBA methods as
well as between the two hMPV strains A and B were observed.
The lower limits of detection of hMPV strains A and B by
real-time RT-PCR was 50 and 100 copies/RT-PCR, respec-
tively, and that by NASBA was 100 and 1,000 copies/reaction,
respectively (data not shown). Both assays were highly specific
for hMPV detection and failed to amplify RNA from other
respiratory viruses such as influenza A and B viruses, respira-
tory syncytial virus, parainfluenza viruses 1 to 3, adenovirus,
and sudden acute respiratory syndrome coronavirus.
hMPV in adult lung transplant recipients. A total of 234
BAL specimens from 114 lung transplant recipients were
tested for hMPV infection by both real-time RT-PCR and
real-time NASBA. At the time of collection, 156 of these BAL
specimens were from asymptomatic lung transplant recipients
and 78 were from symptomatic patients. Samples were col-
lected spanning a 1-year period from May 2004 to April 2005.
The patients’ ages ranged from 22 to 75 years old, with an
average age of 51.7. The cohort was comprised of 41.2% males
and 58.8% females.
All samples included in the study were extracted and ampli-
fied without inhibition, as evidenced by positive EAV cyclic
threshold values (data not shown). Out of 114 patients, 5
(4.3%) specimens from different patients were positive for
hMPV by either RT-PCR or NASBA, all occurring during the
late winter season between February and April 2005 (Fig. 2A).
Two of these specimens were positive by both assays (Table 1).
FIG. 2. Seasonal variation of hMPV prevalence. (A) Graphical representation of the total number of respiratory specimens received from lung
transplant recipients during May 2004 to April 2005 and the number of samples positive for hMPV RNA. (B) Graphical representation of the total
number of respiratory specimens received from pediatric patients during February to May 2005 and the number of hMPV-positive samples
detected during each month.
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Of these five specimens positive for hMPV, three were positive
by RT-PCR (1.2%), while NASBA detected four (1.7%)
hMPV. Of the five hMPV-positive specimens, only one (pa-
tient 1130) was asymptomatic at the time of sample collection,
which was obtained during a routine follow-up, while the other
four (patients 1119, 1124, 1396, and 1422) had respiratory
symptoms and underwent bronchoscopies. There were no sig-
nificant changes in forced expiratory volume in 1 s in lung
transplant recipients following hMPV infection. In addition to
hMPV, two patients, 1124 and 1119, were positive for cyto-
megalovirus pp65 antigenemia, while patient 1396 was also
positive for Candida albicans, Streptococcus viridans, Neisseria
sp., and Propionibacterium sp. infections from BAL specimens.
Patient 1119 was rejecting the graft at the time of hMPV
infection.
An immunofluorescence assay was used to determine the
prevalence of other respiratory viruses in the lung transplant
recipients. In this patient population, one specimen was posi-
tive for adenovirus (0.008%) while none of the specimens
tested positive for influenza A, influenza B, RSV, or paramyxo-
viruses 1 to 3 (data not shown). Respiratory specimens taken
throughout the entire year from these highly immunosup-
pressed patients showed that hMPV infection was the etiologic
agent during the months (February to April) when hMPV is
prevalent in the community (Fig. 2A).
hMPV in children evaluated for pertussis. A total of 232
nasopharyngeal samples, each from a different pediatric pa-
tient undergoing clinical evaluation for pertussis, were tested
for hMPV infection by real-time RT-PCR and NASBA. This
group of patients had a median age of 3 years, and 53.5% were
males. Both assays together detected hMPV RNA in a total of
23 (9.9%) specimens. Twenty-two (9.4%) specimens were pos-
itive for hMPV RNA by real-time RT-PCR, and 15 (6.4%)
were positive by NASBA. Of the 22 RT-PCR positive speci-
mens, 8 were negative by NASBA, whereas RT-PCR failed to
detect only 1 of the 15 NASBA-positive samples (Table 2).
Other pathogens detected in this group during the same
time period included Bordetella pertussis, which was detected
by PCR from 17 specimens (7.3%); RSV, which was detected
by R-Mix shell vial culture and immunofluorescent staining
from 5 specimens (2.1%); and Mycoplasma pneumoniae, which
was detected from 1 (0.4%) respiratory specimen. Though
tested on different respiratory specimen types, none of the
hMPV-positive patients were coinfected with any of the other
pathogens. The hMPV positivity peaked during the month of
March and disappeared by May (Fig. 2B).
DISCUSSION
Since its discovery in 2001, hMPV has been found primarily
in children, the elderly, and immunosuppressed individuals.
Diagnosis of hMPV is difficult by the conventional culture
techniques because of slow growth and subtle cytopathic effect.
Real-time RT-PCR has been described previously for rapid
detection of hMPV RNA (5, 16). In this study, we have devel-
oped a real-time RT-PCR assay that is designed to detect the
N gene of all known hMPV lineages. hMPV has two main
genetic lineages, A and B, with two subtypes within each lin-
eage (A1, A2, B1, and B2). The genetic homology at the
nucleotide level within each lineage is 94%, and between each
lineage it is 84% (3). Can97-83 and Can98-75, representative
of strains A2 and B2, respectively, were available for valida-
tion; however, the primers and probe for the real-time RT-
PCR assay were designed to detect all four known genetic
lineages based on available sequence data. In addition to the
real-time RT-PCR, we also used a real-time NASBA assay
available for hMPV from bioMerieux. Amplification of hMPV
genotype B had a lower sensitivity than genotype A by both of
the molecular methods of detection. This was probably due to
the differences in the nucleotide homology between genotypes
A and B (2, 4) in clinical isolates. NASBA was able to detect
two additional specimens that were negative by RT-PCR in the
transplant group, whereas in the pediatric group, RT-PCR
detected eight hMPV RNA-positive specimens that NASBA
failed to detect. These discrepancies between the two tests
could be due to their different target regions in the hMPV
genome or to a low concentration of hMPV RNA.
Since it has been suggested that hMPV can cause respiratory
infection in immunocompromised individuals, we examined its
incidence in lung transplant recipients. Out of 114 patients
tested at different time intervals, hMPV RNA was detected in
TABLE 1. Associated clinical data from specimens positive for hMPV RNAa
Study
identity no.
Test result Respiratory symptoms
present
Type of lung
transplant Rejection
Baseline FEV1c
(PFEV1) FEV1
b
TaqMan RT-PCR NASBA
1119 Positive Negative Yes Heart/lung Minimal ACRd 2.62 1.18
1124 Positive Positive Yes Double No ND 2.78
1130 Positive Positive No Left single No 1.43 1.5
1396 Negative Positive Yes Heart/lung No 1.53 1.63
1422 Negative Positive Yes Double No ND 1.23
a The clinical data correspond to the time at which the specimens were collected for hMPV RNA detection.
b FEV1, forced expiratory volume in 1 s.
c Baseline FEV1 (PFEV1), preceding FEV1 values prior to the onset of symptoms within a month. ND, not done.
d ACR, acute rejection.
TABLE 2. Comparison of real-time RT-PCR and NASBA assays
for detection of hMPV RNA in pediatric patientsa
Real-time RT-PCR
test result
No. NASBA
positive
No. NASBA
negative Total
Positive 14 8 22 (9.4%)
Negative 1 209 210
Total 15 (6.4%) 217 232
a The numbers in parentheses represent percentages of positives in the total
population tested.
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5 patients (4.3%) by either RT-PCR or NASBA. The onset
of hMPV infection varied from less than 1 month to about 1
year posttransplant. Out of the 156 specimens collected
from asymptomatic patients, only 1 (0.6%) tested positive for
hMPV, while 4 (5.1%) were positive from symptomatic pa-
tients. The infection was not persistent and resolved without
major complications. However, compared to other respiratory
infections, hMPV was a predominant infection in this cohort of
transplant recipients. Recent studies by Gerna et al. (7) and
Larcher et al. (13) have found a high prevalence of hMPV in
symptomatic lung transplant recipients. However, Kumar et al.
(11) observed hMPV as the etiologic agent in only 1 of 50
patients with respiratory tract infections from lung transplant
recipients.
As expected and in agreement with previous studies (12,
20, 28), a higher prevalence of hMPV infection was ob-
served in symptomatic children. Surprisingly, hMPV was the
predominant infection in this cohort, followed by Bordetella
pertussis and RSV. Also, coinfection of hMPV infection was
not observed with other respiratory pathogens. Our study
further confirms previous data suggesting a higher preva-
lence of hMPV infection during the months of February to
April (6, 22).
In conclusion, using two molecular biology-based assays we
have examined the prevalence of hMPV infection in two di-
verse patient populations. In lung transplant recipients, 4.3%
of patients showed evidence of hMPV infection, most of whom
were symptomatic at the time of specimen collection. In the
pediatric population undergoing evaluation for pertussis, how-
ever, a high prevalence (9.9%) of hMPV infection was ob-
served. These data and the seasonal predominance of hMPV
infection suggest that it is not an opportunistic pathogen that
selectively infects immunosuppressed patients. Further studies
to determine the prevalence of hMPV infection in immuno-
suppressed individuals are needed.
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